These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25059456)

  • 1. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®.
    Kollewe K; Mohammadi B; Köhler S; Pickenbrock H; Dengler R; Dressler D
    J Neural Transm (Vienna); 2015 Mar; 122(3):427-31. PubMed ID: 25059456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)).
    Dressler D; Tacik P; Adib Saberi F
    J Neural Transm (Vienna); 2014 Jan; 121(1):29-31. PubMed ID: 23913131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.
    Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
    Neurotox Res; 2009 Apr; 15(3):224-31. PubMed ID: 19384595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.
    Nüssgens Z; Roggenkämper P
    Graefes Arch Clin Exp Ophthalmol; 1997 Apr; 235(4):197-9. PubMed ID: 9143885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
    Jankovic J
    Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin therapy: reduction of injection site pain by pH normalisation.
    Dressler D; Adib Saberi F; Bigalke H
    J Neural Transm (Vienna); 2016 May; 123(5):527-31. PubMed ID: 27002815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
    Saad J; Gourdeau A
    J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine use of Xeomin in patients previously treated with Botox: long term results.
    Dressler D
    Eur J Neurol; 2009 Dec; 16 Suppl 2():2-5. PubMed ID: 20002739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
    Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
    Marchetti A; Magar R; Findley L; Larsen JP; Pirtosek Z; Růzicka E; Jech R; Sławek J; Ahmed F
    Mov Disord; 2005 Aug; 20(8):937-44. PubMed ID: 15810022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
    Frevert J
    Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing Botox and Xeomin for axillar hyperhidrosis.
    Dressler D
    J Neural Transm (Vienna); 2010 Mar; 117(3):317-9. PubMed ID: 20143241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
    Yun JY; Kim JW; Kim HT; Chung SJ; Kim JM; Cho JW; Lee JY; Lee HN; You S; Oh E; Jeong H; Kim YE; Kim HJ; Lee WY; Jeon BS
    Mov Disord; 2015 Feb; 30(2):206-13. PubMed ID: 25476727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose.
    Badarny S; Ibrahim R; Susel Z; Zaina A; Nasar R; Badarny Y
    Medicine (Baltimore); 2021 Jun; 100(25):e26481. PubMed ID: 34160460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
    Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
    Eur J Neurol; 2009 Mar; 16(3):392-8. PubMed ID: 19364366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
    Scaglione F
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.